Literature DB >> 22322322

Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features.

Jaime Prat1.   

Abstract

Malignant epithelial tumors (carcinomas) are the most common ovarian cancers and also the most lethal gynecological malignancies. Based on histopathology and molecular genetic alterations, ovarian carcinomas are divided into five main types (high-grade serous (70%), endometrioid (10%), clear cell (10%), mucinous (3%), and low-grade serous carcinomas (<5%)) that account for over 95% of cases. These types are essentially distinct diseases, as indicated by differences in epidemiological and genetic risk factors, precursor lesions, patterns of spread, and molecular events during oncogenesis, response to chemotherapy, and prognosis. For a successful specific treatment, reproducible histopathological diagnosis of the tumor cell type is critical. The five tumor types are morphologically diverse and resemble carcinomas of the uterus. Actually, recent investigations have demonstrated that a significant number of cancers, traditionally thought to be primary ovarian tumors (particularly serous, endometrioid, and clear cell carcinomas), originate in the fallopian tube and the endometrium and involve the ovary secondarily. This review summarizes recent advances in the molecular pathology which have greatly improved our understanding of the biology of ovarian carcinoma and are also relevant to patient management.

Entities:  

Mesh:

Year:  2012        PMID: 22322322     DOI: 10.1007/s00428-012-1203-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  81 in total

1.  Alternate molecular genetic pathways in ovarian carcinomas of common histological types.

Authors:  Julia Willner; Kaitlyn Wurz; Kimberly H Allison; Vijaya Galic; Rochelle L Garcia; Barbara A Goff; Elizabeth M Swisher
Journal:  Hum Pathol       Date:  2007-01-29       Impact factor: 3.466

2.  Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.

Authors:  K Obata; S J Morland; R H Watson; A Hitchcock; G Chenevix-Trench; E J Thomas; I G Campbell
Journal:  Cancer Res       Date:  1998-05-15       Impact factor: 12.701

3.  Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.

Authors:  Russell Vang; Allen M Gown; Lee-Shu-Fune Wu; Todd S Barry; Darren T Wheeler; Anna Yemelyanova; Jeffrey D Seidman; Brigitte M Ronnett
Journal:  Mod Pathol       Date:  2006-09-15       Impact factor: 7.842

4.  Mutation of the PIK3CA gene in ovarian and breast cancer.

Authors:  Ian G Campbell; Sarah E Russell; David Y H Choong; Karen G Montgomery; Marianne L Ciavarella; Christine S F Hooi; Briony E Cristiano; Richard B Pearson; Wayne A Phillips
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

5.  beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.

Authors:  G Moreno-Bueno; C Gamallo; L Pérez-Gallego; J C de Mora; A Suárez; J Palacios
Journal:  Diagn Mol Pathol       Date:  2001-06

6.  Frequency of BRCA1 dysfunction in ovarian cancer.

Authors:  John P Geisler; Melanie A Hatterman-Zogg; Jennifer A Rathe; Richard E Buller
Journal:  J Natl Cancer Inst       Date:  2002-01-02       Impact factor: 13.506

7.  Clonal analysis favours a monoclonal origin for serous borderline tumours with peritoneal implants.

Authors:  N L Sieben; G M J M Roemen; J Oosting; G J Fleuren; M van Engeland; J Prat
Journal:  J Pathol       Date:  2006-12       Impact factor: 7.996

8.  Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives.

Authors:  Debra A Bell; Teri A Longacre; Jaime Prat; Elise C Kohn; Robert A Soslow; Lora H Ellenson; Anais Malpica; Mark H Stoler; Robert J Kurman
Journal:  Hum Pathol       Date:  2004-08       Impact factor: 3.466

9.  Serous carcinogenesis in the fallopian tube: a descriptive classification.

Authors:  Elke Jarboe; Ann Folkins; Marisa R Nucci; David Kindelberger; Ronny Drapkin; Alexander Miron; Yonghee Lee; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2008-01       Impact factor: 2.762

10.  WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.

Authors:  M Al-Hussaini; A Stockman; H Foster; W G McCluggage
Journal:  Histopathology       Date:  2004-02       Impact factor: 5.087

View more
  157 in total

1.  The role of metabolic tumor volume and total lesion glycolysis on ¹⁸F-FDG PET/CT in the prognosis of epithelial ovarian cancer.

Authors:  Jeong Won Lee; Arthur Cho; Jae-Hoon Lee; Mijin Yun; Jong Doo Lee; Young Tae Kim; Won Jun Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-23       Impact factor: 9.236

Review 2.  Molecular staging of gynecological cancer: What is the future?

Authors:  Pratibha S Binder; Jaime Prat; David G Mutch
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2015-03-04       Impact factor: 5.237

3.  Adhering to the 2014 WHO terminology on borderline ovarian tumors.

Authors:  Jaime Prat
Journal:  Virchows Arch       Date:  2017-02       Impact factor: 4.064

Review 4.  Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.

Authors:  Khalid El Bairi; Abdul Hafeez Kandhro; Adel Gouri; Wafaa Mahfoud; Noureddine Louanjli; Brahim Saadani; Said Afqir; Mariam Amrani
Journal:  Cell Oncol (Dordr)       Date:  2016-12-15       Impact factor: 6.730

5.  Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients.

Authors:  Magdalena Koczkowska; Natalia Krawczynska; Maciej Stukan; Alina Kuzniacka; Izabela Brozek; Marcin Sniadecki; Jaroslaw Debniak; Dariusz Wydra; Wojciech Biernat; Piotr Kozlowski; Janusz Limon; Bartosz Wasag; Magdalena Ratajska
Journal:  Cancers (Basel)       Date:  2018-11-14       Impact factor: 6.639

6.  Analysis of wntless (WLS) expression in gastric, ovarian, and breast cancers reveals a strong association with HER2 overexpression.

Authors:  Jonathan Stewart; Jacqueline James; Glenn W McCluggage; Stephen McQuaid; Kenneth Arthur; David Boyle; Paul Mullan; Darragh McArt; Benedict Yan; Gareth Irwin; D Paul Harkin; Lei Zhengdeng; Chee-Wee Ong; Jia Yu; David M Virshup; Manuel Salto-Tellez
Journal:  Mod Pathol       Date:  2014-09-26       Impact factor: 7.842

Review 7.  Prognostic biomarkers in endometrial and ovarian carcinoma.

Authors:  Xavier Matias-Guiu; Ben Davidson
Journal:  Virchows Arch       Date:  2014-02-07       Impact factor: 4.064

8.  Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.

Authors:  Larissa Dettmar; Nancy Ahmed; Matthias Kotzsch; Sandra Diersch; Rudolf Napieralski; Dalila Darmoul; Manfred Schmitt; Wilko Weichert; Marion Kiechle; Julia Dorn; Viktor Magdolen
Journal:  J Cancer Res Clin Oncol       Date:  2018-03-15       Impact factor: 4.553

Review 9.  Low-grade epithelial ovarian cancer: what a radiologist should know.

Authors:  Sherif Elsherif; Sanaz Javadi; Chitra Viswanathan; Silvana Faria; Priya Bhosale
Journal:  Br J Radiol       Date:  2019-01-31       Impact factor: 3.039

10.  A novel truncated form of HMGA2 in tumors of the ovaries.

Authors:  Antonio Agostini; Ioannis Panagopoulos; Ben Davidson; Claes Goran Trope; Sverre Heim; Francesca Micci
Journal:  Oncol Lett       Date:  2016-06-29       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.